Article
ImmunoVaccine Technologies to Help Strengthen Canada's Defenses Against Biological Threats
Author(s):
ImmunoVaccine Technologies, Inc. (IVT, Halifax, Nova Scotia), a vaccine development company, has signed a three-year research agreement with Defence Research and Development Canada (DRDC).
ImmunoVaccine Technologies, Inc. (IVT, Halifax, Nova Scotia), a vaccine development company, has signed a three-year research agreement with Defence Research and Development Canada (DRDC). The research collaboration involves the preclinical application of IVT’s DepoVax vaccine formulation to anthrax antigens to explore new methods to prevent, prepare for, and respond to biological threats.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
